These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
333 related articles for article (PubMed ID: 9122231)
21. Partial correction of the alpha-galactosidase A deficiency and reduction of glycolipid storage in Fabry mice using synthetic vectors. Przybylska M; Wu IH; Zhao H; Ziegler RJ; Tousignant JD; Desnick RJ; Scheule RK; Cheng SH; Yew NS J Gene Med; 2004 Jan; 6(1):85-92. PubMed ID: 14716680 [TBL] [Abstract][Full Text] [Related]
22. Correction of cardiac abnormalities in fabry mice by direct intraventricular injection of a recombinant lentiviral vector that engineers expression of alpha-galactosidase A. Yoshimitsu M; Higuchi K; Dawood F; Rasaiah VI; Ayach B; Chen M; Liu P; Medin JA Circ J; 2006 Nov; 70(11):1503-8. PubMed ID: 17062978 [TBL] [Abstract][Full Text] [Related]
23. Therapeutic Strategy for Fabry Disease by Intravenous Administration of Adeno-Associated Virus 9 in a Symptomatic Mouse Model. Hayashi Y; Sehara Y; Watano R; Ohba K; Takayanagi Y; Sakiyama Y; Muramatsu K; Mizukami H Hum Gene Ther; 2024 Mar; 35(5-6):192-201. PubMed ID: 38386497 [TBL] [Abstract][Full Text] [Related]
24. Reduced alpha-Gal A enzyme activity in Fabry fibroblast cells and Fabry mice tissues induced by serum from antibody positive patients with Fabry disease. Ohashi T; Iizuka S; Ida H; Eto Y Mol Genet Metab; 2008 Jul; 94(3):313-8. PubMed ID: 18456533 [TBL] [Abstract][Full Text] [Related]
25. Naked plasmid DNA-based alpha-galactosidase A gene transfer partially reduces systemic accumulation of globotriaosylceramide in Fabry mice. Nakamura G; Maruyama H; Ishii S; Shimotori M; Kameda S; Kono T; Miyazaki J; Kulkarni AB; Gejyo F Mol Biotechnol; 2008 Feb; 38(2):109-19. PubMed ID: 18219591 [TBL] [Abstract][Full Text] [Related]
26. α-Galactosidase A knockout mice: progressive organ pathology resembles the type 2 later-onset phenotype of Fabry disease. Bangari DS; Ashe KM; Desnick RJ; Maloney C; Lydon J; Piepenhagen P; Budman E; Leonard JP; Cheng SH; Marshall J; Thurberg BL Am J Pathol; 2015 Mar; 185(3):651-65. PubMed ID: 25553976 [TBL] [Abstract][Full Text] [Related]
27. Infusion of alpha-galactosidase A reduces tissue globotriaosylceramide storage in patients with Fabry disease. Schiffmann R; Murray GJ; Treco D; Daniel P; Sellos-Moura M; Myers M; Quirk JM; Zirzow GC; Borowski M; Loveday K; Anderson T; Gillespie F; Oliver KL; Jeffries NO; Doo E; Liang TJ; Kreps C; Gunter K; Frei K; Crutchfield K; Selden RF; Brady RO Proc Natl Acad Sci U S A; 2000 Jan; 97(1):365-70. PubMed ID: 10618424 [TBL] [Abstract][Full Text] [Related]
28. Long-term systemic therapy of Fabry disease in a knockout mouse by adeno-associated virus-mediated muscle-directed gene transfer. Takahashi H; Hirai Y; Migita M; Seino Y; Fukuda Y; Sakuraba H; Kase R; Kobayashi T; Hashimoto Y; Shimada T Proc Natl Acad Sci U S A; 2002 Oct; 99(21):13777-82. PubMed ID: 12370426 [TBL] [Abstract][Full Text] [Related]
30. In vitro inhibition and intracellular enhancement of lysosomal alpha-galactosidase A activity in Fabry lymphoblasts by 1-deoxygalactonojirimycin and its derivatives. Asano N; Ishii S; Kizu H; Ikeda K; Yasuda K; Kato A; Martin OR; Fan JQ Eur J Biochem; 2000 Jul; 267(13):4179-86. PubMed ID: 10866822 [TBL] [Abstract][Full Text] [Related]
31. Autophagy-lysosome pathway associated neuropathology and axonal degeneration in the brains of alpha-galactosidase A-deficient mice. Nelson MP; Tse TE; O'Quinn DB; Percival SM; Jaimes EA; Warnock DG; Shacka JJ Acta Neuropathol Commun; 2014 Feb; 2():20. PubMed ID: 24529306 [TBL] [Abstract][Full Text] [Related]
32. Expression of genes and their responses to enzyme replacement therapy in a Fabry disease mouse model. Park ES; Choi JO; Park JW; Lee MH; Park HY; Jung SC Int J Mol Med; 2009 Sep; 24(3):401-7. PubMed ID: 19639234 [TBL] [Abstract][Full Text] [Related]
33. In vitro study of encapsulation therapy for Fabry disease using genetically engineered CHO cell line. Naganawa Y; Ohsugi K; Kase R; Date I; Sakuraba H; Sakuragawa N Cell Transplant; 2002; 11(4):325-9. PubMed ID: 12162373 [TBL] [Abstract][Full Text] [Related]
34. Preclinical evaluation of FLT190, a liver-directed AAV gene therapy for Fabry disease. Jeyakumar JM; Kia A; Tam LCS; McIntosh J; Spiewak J; Mills K; Heywood W; Chisari E; Castaldo N; Verhoef D; Hosseini P; Kalcheva P; Cocita C; Miranda CJ; Canavese M; Khinder J; Rosales C; Hughes D; Sheridan R; Corbau R; Nathwani A Gene Ther; 2023 Jun; 30(6):487-502. PubMed ID: 36631545 [TBL] [Abstract][Full Text] [Related]
35. Retroviral coexpression of a multidrug resistance gene (MDR1) and human alpha-galactosidase A for gene therapy of Fabry disease. Sugimoto Y; Aksentijevich I; Murray GJ; Brady RO; Pastan I; Gottesman MM Hum Gene Ther; 1995 Jul; 6(7):905-15. PubMed ID: 7578409 [TBL] [Abstract][Full Text] [Related]
36. Efficient correction of Fabry mice and patient cells mediated by lentiviral transduction of hematopoietic stem/progenitor cells. Yoshimitsu M; Higuchi K; Ramsubir S; Nonaka T; Rasaiah VI; Siatskas C; Liang SB; Murray GJ; Brady RO; Medin JA Gene Ther; 2007 Feb; 14(3):256-65. PubMed ID: 16929352 [TBL] [Abstract][Full Text] [Related]